FDA Brief

Warning letters Drugs

FDA warning letter to

Handelnine Global, LLC dba Navafresh

High riskIssued Nov 17, 2025Posted Nov 25, 2025Center for Drug Evaluation and Research (CDER)

Navafresh sells unapproved Ayurvedic drugs online, and its Rheumacare Capsules contain about 7,000 times the lead level of concern.

What happened

FDA reviewed the navafresh.com website in September 2025 and found ten products offered for sale in the United States with claims to treat diseases such as cancer, diabetes, measles and Parkinson's. FDA also obtained and tested a sample of Rheumacare Capsules; two lots contained lead at 9,588 to 11,124 ppm, roughly 7,000 times the amount indicating harmful exposure, and early results also pointed to mercury, strychnine, brucine and arsenic. None of the products has an FDA-approved application.

What FDA found

  1. The products are new drugs sold without an FDA-approved application, which the law requires before marketing.

    Section 505(a), FD&C Act, 21 U.S.C. 355(a)
  2. Rheumacare Capsules contain unsafe lead levels and were not made under good manufacturing practice (CGMP), the basic quality rules for drug production, so the product is adulterated.

    Section 501(a)(2)(B), FD&C Act, 21 U.S.C. 351(a)(2)(B)
  3. The Rheumacare label does not declare that the product contains lead, which makes the labeling false or misleading.

    Section 502(a), FD&C Act, 21 U.S.C. 352(a)
  4. Rheumacare is dangerous to health when used as the label directs, which makes it misbranded.

    Section 502(j), FD&C Act, 21 U.S.C. 352(j)
  5. Website and packaging claims that the products treat cancer, diabetes, measles, Parkinson's and other diseases make them drugs under the law.

    Section 201(g)(1), FD&C Act, 21 U.S.C. 321(g)(1)
  6. Shipping these unapproved and misbranded drugs in interstate commerce is a prohibited act.

    Sections 301(a) and 301(d), FD&C Act, 21 U.S.C. 331(a) and 331(d)

What FDA wants

FDA tells the company to write to CDER's Office of Unapproved Drugs and Labeling Compliance within fifteen working days, describing each corrective step taken, how recurrence will be prevented, and including supporting documents. If corrections cannot be finished in that time, the company must say why and give a completion date.

Who should pay attention

  • online marketplaces and retailers listing imported Ayurvedic drugs
  • brands and distributors that import Ayurvedic products from India
  • consumers using herbal remedies for arthritis, diabetes or eye problems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Purcell International

    Purcell International imported cinnamon apple sauce linked to lead contamination without adequate foreign supplier verification.

    High risk
  2. WANABANA USA LLC

    WanaBana USA LLC failed to verify foreign supplier safety for lead-contaminated apple cinnamon puree pouches.

    High risk
  3. AUSTROFOOD S.A.S.

    Austrofood's apple cinnamon puree pouches were adulterated with extremely high lead from cinnamon; hazard controls failed.

    High risk
  4. Dollar Tree Inc.

    Dollar Tree continued offering recalled WanaBana apple cinnamon puree pouches with extremely high lead levels, FDA says.

    High risk